PT-141 (Bremelanotide)
Melanocortin receptor agonist studied for its central action on sexual response pathways. The active compound is FDA-approved as Vyleesi.
Research Areas
Scientific Background
PT-141 (Bremelanotide) is a cyclic heptapeptide analog of alpha-MSH that acts as an agonist at melanocortin receptors, primarily MC4R in the central nervous system. Unlike vasodilator-based approaches, it works through neural pathways in the hypothalamus to influence sexual arousal.
Purity & Provenance
Why quality matters for research validity
PT-141 is a cyclic heptapeptide. Research-grade material requires HPLC ≥98% purity with mass spec confirmation.
Areas of Investigation
Laboratory Information
Technical specifications for research settings
This compound is intended for qualified scientific research only. Not for human or veterinary use. Not for diagnostic or therapeutic applications. Researchers must comply with all applicable regulations in their jurisdiction.
Store lyophilized at -20°C. Protect from light.
Lyophilized powder
>98% by HPLC
Soluble in bacteriostatic water
For in vitro neuroscience research applications.
Deepen Your Research
Published literature and clinical trial registries
Published Literature
Bremelanotide was studied in the RECONNECT phase 3 clinical trials, leading to FDA approval as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women. Clayton et al. (2019, Obstetrics & Gynecology) reported the pivotal trial outcomes.
Regulatory Classification
The active compound bremelanotide is FDA-approved as Vyleesi for a specific indication. Material sold here is for qualified research purposes only, not for human use.
Important Research Notice
This information is compiled from scientific literature for educational purposes only. This website does not sell, distribute, or recommend any compounds for human use. All compounds discussed are for qualified research purposes only.